^
    1d
    FORTITUDE-301: A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (clinicaltrials.gov)
    P1/2, N=260, Completed, Amgen | Active, not recruiting --> Completed
    Trial completion • Pan tumor
    |
    FGFR2 overexpression
    |
    bemarituzumab (AMG 552)
    1d
    Assessment of Safety, Tolerability and PK Profile of MSP008-22 in Patients With Advanced Solid Tumours (clinicaltrials.gov)
    P1, N=7, Completed, Godavari Biorefineries Limited | Not yet recruiting --> Completed | N=27 --> 7 | Trial completion date: Jan 2023 --> Jan 2026 | Trial primary completion date: Dec 2022 --> Jan 2026
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    1d
    SUSPECT2: Lymph Drainage Mapping for Tailoring Elective Nodal Irradiation in Head and Neck Cancer (clinicaltrials.gov)
    P=N/A, N=90, Active, not recruiting, The Netherlands Cancer Institute | Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2025 --> Jan 2026
    Enrollment closed • Trial primary completion date
    1d
    Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck (clinicaltrials.gov)
    P2, N=50, Completed, Yale University | Active, not recruiting --> Completed
    Trial completion
    |
    Erbitux (cetuximab) • Gilotrif (afatinib)
    2d
    Interventional effects of mesenchymal stem cells on epithelial-mesenchymal transition in head and neck squamous cell carcinoma and underlying mechanisms: a systematic review and meta-analysis of in vitro studies. (PubMed, Front Immunol)
    The existing in vitro evidence suggests that mesenchymal stem cells may exhibit a potential to promote EMT in HNSCC, potentially regulating tumor progression through multiple signaling pathway networks and providing new potential targets for future therapies targeting the TME. However, more high-quality, standardized in vivo and in vitro studies are needed to further validate the related mechanisms and therapeutic potential.
    Clinical • Preclinical • Retrospective data • Review • Journal
    |
    FGF19 (Fibroblast growth factor 19) • FGFR4 (Fibroblast growth factor receptor 4) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • STAT3 (Signal Transducer And Activator Of Transcription 3) • TGFB1 (Transforming Growth Factor Beta 1) • IL6R (Interleukin 6 receptor) • CXCR2 (Chemokine (C-X-C motif) receptor 2)
    2d
    IS THERE A PROGNOSTIC ROLE OF FOCAL ADHESION KINASE AND CD8 IN SQUAMOUS CELL HEAD AND NECK CANCER TREATED WITH RADIOTHERAPY? (PubMed, Acta Clin Croat)
    Patients with low expression of FAK had significantly less relapses. The prognostic role of FAK and CD8 expression in SCHNC patients treated with radiotherapy was not proven.
    Journal
    |
    CD8 (cluster of differentiation 8) • PTK2 (Protein Tyrosine Kinase 2)
    2d
    Current status and perspective of immunotherapy for head and neck squamous cell carcinoma. (PubMed, Expert Opin Investig Drugs)
    Currently, pembrolizumab plus or less chemotherapy is recommended in patients with CPS > 1 in metastatic HNSCC, while nivolumab is used in the second line setting for platinum-refractory disease. This review discusses both completed and ongoing clinical trials with PD-1/PDL-1 and new checkpoint inhibitors and immunotherapies. It also addresses mechanisms of resistance to immunotherapy, potential therapeutic strategies to overcome this resistance, biomarkers and side effects.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • TNFRSF4 (TNF Receptor Superfamily Member 4)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab)
    2d
    Personalized ctDNA analysis for detection of residual disease and recurrence in surgically treated HNSCC patients. (PubMed, NPJ Precis Oncol)
    Plasma ctDNA detected ≥14 days post-surgery identified 91.3% of recurrences, with lead times up to 500 days before clinical confirmation. These results highlight the value of serial ctDNA monitoring for early relapse detection and potentially improved treatment guidance in HNSCC.
    Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker • Circulating tumor DNA
    |
    TMB (Tumor Mutational Burden) • PD-1 (Programmed cell death 1)
    3d
    JADE: phase 3 study of sequential dostarlimab post chemoradiotherapy in patients with locally advanced unresected HNSCC. (PubMed, Future Oncol)
    Treatment of LA HNSCC is multimodal and may include concomitant cisplatin-based chemoradiotherapy (CRT) or surgery; however, recurrence rates are high, and there is an unmet need for new treatments. The primary endpoint is event-free survival, with overall survival as a key secondary endpoint; safety and tolerability, pharmacokinetics, immunogenicity, biomarkers, and patient-reported outcomes will also be assessed. www.clinicaltrials.gov identifier is NCT06256588.
    P3 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • MSI-H/dMMR
    |
    cisplatin • Jemperli (dostarlimab-gxly)
    3d
    A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze) (clinicaltrials.gov)
    P2, N=150, Recruiting, University of Michigan Rogel Cancer Center | Trial completion date: Dec 2029 --> Dec 2030 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    4d
    COMBINE-EGFR-1: A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers (clinicaltrials.gov)
    P1/2, N=933, Recruiting, Regeneron Pharmaceuticals | Trial completion date: Dec 2026 --> Apr 2027
    Trial completion date
    |
    Avastin (bevacizumab) • Libtayo (cemiplimab-rwlc) • Lonsurf (trifluridine/tipiracil)
    4d
    A Phase II Clinical Trial of Anti-EGFR Antibody-drug Conjugate (ADC) Combined With or Without Immune Checkpoint Inhibitors in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=120, Not yet recruiting, West China Hospital
    New P2 trial • Checkpoint inhibition
    |
    Anniko (penpulimab-kcqx) • Meiyouheng (becotatug vedotin) • Yidafan (ivonescimab) • becotarug (JMT101)